Pharming Group to Present Pediatric APDS Data on Lenolisib at CIS 2026 Meeting

Pharming Group will present new data on leniolisib at the Clinical Immunology Society (CIS) 2026 Annual Meeting, including pediatric data for Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) and clinical experience in Common Variable Immunodeficiency (CVID) and related disorders. The presentations will offer insights into the use of leniolisib in treating these immune disorders.

The company’s presentations will cover the efficacy and safety of leniolisib in pediatric patients with APDS, providing detailed data from clinical trials. Additional presentations will share real-world clinical experiences with leniolisib in patients with CVID and related immune disorders, highlighting the drug’s impact on various aspects of these conditions. The CIS Annual Meeting serves as a platform for sharing advancements in clinical immunology and related fields.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 7, 2026

Author

GOAI